Le Lézard
Classified in: Health
Subject: SVY

US Hemostasis Diagnostics Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers


LONDON, Nov. 22, 2017 /PRNewswire/ --

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200.



Download the full report: https://www.reportbuyer.com/product/3963911

Summary

This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the next five years.

The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Coagulation Tests

Activated Clotting Time (ACT) (1), Activated Protein C Resistance,
Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time,
D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII,  Factor IX,
Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII,
Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation,
Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen,
Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S,
Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time,
Von Willebrandâ?tms Factor Fav/Ag, and others.

Sales and Market Share Analysis

- Sales and market shares of major
instrument and reagent suppliers.

Competitive Assessments

- Extensive strategic profiles of
major suppliers and emerging market entrants.

Market Segmentation Analysis

- Comprehensive market
segmentation analysis, including:

   - Hospitals
   - Commercial/Private Laboratories
   - Physician Offices

- Test volume forecasts for over 40 major procedures
by market segment.

Current and Emerging Products

- Review of established and emerging procedures.

- Comparison of automated and semi-automated
analyzers from Diagnostica Stago, Helena, IL,
Siemens, Sysmex and other suppliers.

Technology Review

- Analysis of current and emerging technologies
and their potential market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Strategic Recommendations

- Product development and business expansion
opportunities with significant market appeal.

- "Ideal" product models with tentative
prices and operating characteristics.

- Alternative market penetration
strategies for instrument and reagent suppliers.

- Potential market entry barriers and risks.

Contains 424 pages and 37 tables


Download the full report: https://www.reportbuyer.com/product/3963911

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer


These press releases may also interest you

at 18:16
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 17:56
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIREŽ (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...



News published on and distributed by: